Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13215732 | 0.85 | ALDH1A1 (0.57) | MAPK1SPHK2SPHK1ALDH1A1CRHBP | |
| SCHEMBL9893059 | 0.85 | MAPK1 (0.56) | MAPK1SPHK2SPHK1ALDH1A1CRHBP | |
| SCHEMBL3572935 | 0.84 | ALDH1A1 (0.60) | MAPK1SPHK2SPHK1ALDH1A1CRHBP | |
| SCHEMBL25824759 | 0.84 | MAPK1 (0.55) | MAPK1SPHK2SPHK1ALDH1A1CRHBP | |
| SCHEMBL9131967 | 0.84 | SPHK1 (0.53) | SPHK2SPHK1ALDH1A1GBA1 | |
| SCHEMBL10208473 | 0.84 | SPHK1 (0.70) | SPHK2SPHK1GBA1 | |
| SCHEMBL10355476 | 0.84 | SPHK1 (0.53) | SPHK2SPHK1ALDH1A1GBA1 | |
| SCHEMBL9134554 | 0.84 | SPHK1 (0.53) | SPHK2SPHK1ALDH1A1GBA1 | |
| SCHEMBL14395220 | 0.83 | MAPK1 (0.54) | MAPK1SPHK2SPHK1ALDH1A1CRHBP | |
| SCHEMBL11990426 | 0.83 | MAPK1 (0.54) | MAPK1SPHK2SPHK1ALDH1A1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MAPK1 1463/4885SPHK2 238/4885SPHK1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.